Endari is a prescription medication for people ages 5 and older with sickle cell disease (SCD). Its use is focused on supporting the management of disruptive manifestations of the condition. Endari is indicated to reduce the acute complications of SCD.

---

Easing Acute Sickle Cell Complications

Endari is commonly used to help manage the risk associated with SCD's sudden, severe episodes, which constitute the disease's acute complications. It is applied in addressing symptoms associated with these disruptive events, which may involve short-term hospitalizations, thereby lessening the overall burden of symptoms. This supportive therapy is relevant for situations involving pain crises (vaso-occlusive crises) and acute chest syndrome.

“Endari may assist with maintaining comfort and helps patients cope more steadily with these intensely difficult, episodic flare-ups.”

Addressing Painful Episodes and Symptom Clusters

This medication is applied in addressing the most common and distressing symptom group in SCD: pain crises (VOCs). It supports patients during phases where symptoms become more noticeable and create noticeable physiological strain. Endari is relevant for easing conditions characterized by periods of heightened symptoms and potential functional instability.

Quick Fact: Relevant for Symptoms of Episodic Pain (VOCs)

Supporting Symptom Management and Stability

Endari is considered relevant as it may play a role in managing the symptoms that are linked to hospitalizations for SCD-related pain, thereby contributing to easing the overall symptom load and supports patients during episodes of heightened discomfort. It is commonly used when short-term symptomatic assistance is needed.

Eligibility Map: Who can and cannot use Endari — Official Regulatory Information

Eligibility Scope

Category	Regulatory Statement
Populations for whom use is allowed	Adult and pediatric patients 5 years of age and older diagnosed with sickle cell disease (SCD).
Populations for whom use is contraindicated	None. The official prescribing information lists no labeled absolute contraindications for use.
Age-related eligibility rules	Safety and effectiveness have not been established in children younger than 5 years old.
Condition-specific eligibility rules	Use is permitted, but caution is advised in patients with pre-existing renal or hepatic impairment. Routine monitoring of organ function is recommended.
Pregnancy and lactation eligibility status	No available human data inform the risk during pregnancy. For lactation, there is no information on the effects of supplementation on the breastfed infant.
Eligibility-related restrictions	Older adults require cautious dose selection, reflecting the potential for decreased renal, hepatic, or cardiac function.

---

Eligibility Classifications (High-Level)

Category	Regulatory Statement
Eligibility severity classification	No Absolute Contraindication. Restrictions are precautionary, based on age data gaps or organ function.
Eligibility-context constraints	Requires a minimum age of 5 years and an established Sickle Cell Disease diagnosis.

---

Resulting Eligibility Structure

Official regulatory documents establish Endari's primary eligibility based on two factors: the patient's Sickle Cell Disease diagnosis and a minimum age of 5 years. The medicine's labeling does not list any absolute prohibitions against its use. Instead, constraints focus on the lack of established safety data for children under 5, and a requirement for caution and monitoring in patients with reduced renal or hepatic function.

Interactions with other medicines and products

Official Regulatory Status: Drug-Drug Interactions

The official regulatory profile for Endari (L-Glutamine oral powder) is primarily defined by the absence of documented interaction studies. The prescribing information, as outlined by the U.S. Food and Drug Administration, explicitly states that no formal studies evaluating the interaction of Endari with other medicinal products have been conducted.

As a result, no specific interacting medicines, product categories, or mechanistic bases for interaction (such as CYP enzyme inhibition or induction) are officially documented in the label. No drug combinations are formally prohibited or designated as contraindicated for co-administration.

---

Exposure and Administration Context

Regarding the drug's exposure, regulatory data confirms that co-administration with food results in no significant change in the plasma concentration (AUC or Cmax) of L-Glutamine. Therefore, the regulatory label does not include any mandatory timing rules or separation requirements for taking Endari with meals or other medicines. Interactions with alcohol, herbal products, or other supplements are not explicitly documented.

---

Population-Specific Caution

A population-specific caution related to the drug’s metabolism and clearance is noted. L-Glutamine is metabolized into glutamate and ammonia, and the label indicates that the metabolism of these substances may increase in patients with hepatic dysfunction. This finding is a specific regulatory note related to clearance in this patient population.

How Endari Works

Endari (L-Glutamine) is a metabolic substrate that acts by influencing the intracellular redox balance of red blood cells ( RBCs). Its mechanism involves supplying a critical substrate to facilitate the synthesis of key antioxidant components and maintain cell structure.

---

Modulation of Intracellular Antioxidant Capacity

The drug's primary action involves acting as a precursor for the Glutathione ( GSH) pathway and the NAD redox system within the red blood cell. By increasing the availability of GSH and maintaining a favorable ratio of NADH:( NAD^+ + NADH), L-Glutamine influences the neutralization of Reactive Oxygen Species (ROS). This fundamental action affects the modulation of the cell's internal oxidative environment, influencing the molecular processes that can result in damage.

---

Influence on Red Blood Cell Deformability

The affected antioxidant capacity directly contributes to the maintenance of RBC membrane and structural protein integrity, which are highly susceptible to oxidation. By influencing the cell structure, L-Glutamine affects the cell’s essential deformability (flexibility). This sustained flexibility influences the RBC's threshold for HbS polymerization under reduced oxygen levels, functionally delaying the Point of Sickling ( PoS) threshold, which influences passage through the microvasculature.

How to Use Endari

Endari (L-Glutamine oral powder) is administered as an oral therapy that follows specific, weight-based dosing guidelines. The medicine is intended for long-term use to support the management of acute complications in patients with Sickle Cell Disease.

---

Administration and Preparation

The approved route is oral administration using the powdered formulation. The medicine must be mixed immediately before ingestion with a cold or room temperature beverage, such as water, milk, or juice (approximately 8 ounces), or with soft food like yogurt or applesauce (4 to 6 ounces). The labeling notes that complete dissolution of the powder is not required prior to consumption. The medicine may be taken with or without food.

---

Official Dosing and Frequency

Endari is taken twice daily (BID). The specific dose is determined by the patient's weight category, and the same scale applies to patients aged five years and older:

Patient Weight	Endari Dose Per Administration	Number of Packets
< 30 kg (< 66 lb)	5 grams	1
30 to 65 kg (66 to 143 lb)	10 grams	2
Greater than or equal to 65 kg (Greater than or equal to 143 lb)	15 grams	3

Procedural Rules

Endari is approved for use in patients 5 years of age and older. For older adults, dose selection should be cautious, generally starting at the low end of the dosing range, reflecting potential differences in organ function. If a dose is missed, the patient should take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped; patients must not double the dose to compensate.

Evidence for Reducing Acute Complications

The research record for Endari centers on a randomized, double-blind, placebo-controlled trial. This design is the standard used to establish a medicine's research record. The research was studied for examining the medicine's role in addressing the severity and frequency of painful episodes and other serious events linked to sickle cell disease (SCD). Researchers examined outcomes related to acute complications, specifically focusing on the frequency of vaso-occlusive crises (VOCs), which are common pain crises, and the occurrence of Acute Chest Syndrome (ACS).

Studies monitored these outcomes over a defined observation period of 48 weeks to examine the frequency of these acute events measured in the group receiving L-Glutamine versus the group receiving placebo. The outcomes reflecting daily functioning or activity level and the time between serious episodes were also observed in the study participants. The research describes patterns related to the reported frequency of VOC events and hospital stays observed in the treatment group compared to the placebo group.

---

Studies in Pediatric and Adult Populations

The primary clinical evaluations for Endari was studied for use in a broad age range, including both pediatric patients (ages 5 and older) and adults, up to age 58. This means the research includes data on how the medicine was evaluated in pediatric patients (age 5 and older) as well as in adults. The study population was composed of individuals with the most common types of SCD, and inclusion required a history of experiencing multiple pain crises in the year before the study began.

---

Long-Term Follow-up and Study Duration

The primary evidence that established the research record for Endari was derived from a trial that followed patients for 48 weeks (roughly one year). This duration contributes to the broader evidence landscape by providing insight into short-term changes and episodic symptom patterns. The core data, therefore, reflect the measurements collected over this intermediate-term follow-up duration.

While the primary trial duration was 48 weeks, researchers have also explored outcomes in longer-term settings. These longer follow-up durations were limited and were conducted using less rigorous, non-randomized designs compared to the main clinical trial. Therefore, data show patterns related to outcomes observed in the studies, but the long-term effects are not fully established by the highest quality evidence.

---

Evidence Gaps and Areas for Future Research

Despite the evidence available from the research record, some important areas remain uncertain or insufficiently studied. For instance, the safety and research record for children younger than 5 years of age are not established, meaning there is limited information for this age group.

Similarly, older adults aged 65 and over were insufficiently represented in the pivotal clinical trial. This means the results apply only to the populations studied, and data for this specific group remain insufficient to draw conclusions. Furthermore, the clinical trials did not directly compare Endari against other active treatments for sickle cell disease; the comparison was against an inactive placebo. Comparative evidence is lacking. The evidence highlights what is known — and what is still uncertain — and research is ongoing in the broader scientific community to fill these gaps.

Key Studies & References L-glutamine: MedlinePlus Drug Information (Patient-Focused Overview)

Common questions about Endari (FAQ)

---

Q: Is Endari the same as taking an L-glutamine supplement from the store?

A: Endari is classified as an FDA-approved prescription drug indicated to reduce the acute complications of sickle cell disease. While the active ingredient is L-glutamine, this therapeutic product is a specific, controlled prescription medicine. Store-bought L-glutamine, by contrast, is a dietary supplement.

Q: Is Endari a chemotherapy drug?

A: Official product information indicates that Endari is classified as an amino acid and a metabolic agent. Its mechanism is described as influencing the balance of key substances within red blood cells. It is not classified as a chemotherapy drug.

Q: Why is Endari powder and not a pill?

A: Endari is formulated as a powder for oral use, which is a key part of its intended administration. The powder is formulated to be mixed with a cold or room-temperature beverage or soft food immediately prior to consumption.

Q: Do I need to mix Endari with a specific liquid?

A: Official instructions indicate that the powder can be mixed with common cold or room-temperature beverages, such as water, milk, or juice. It may also be mixed with soft foods, including yogurt or applesauce. Any mixed powder must be consumed immediately.

Q: What are the most commonly reported side effects of Endari?

A: Studies indicate that the most commonly reported side effects (occurring in over 10% of patients) primarily affected the gastrointestinal and nervous systems. These common reactions included constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain, and chest pain.

Q: Can Endari cause stomach issues?

A: In clinical trials, the most commonly reported adverse reactions affecting the gastrointestinal system included specific issues such as constipation, nausea, abdominal pain, and dyspepsia.

Q: Is it common to feel nauseous when starting Endari?

A: Nausea is classified as a Common adverse reaction. This means it was reported in over 10% of patients during the clinical studies used to establish the drug’s safety profile.

Q: Can people with kidney problems use Endari?

A: Official labeling advises caution when Endari is used in patients who have pre-existing renal (kidney) impairment. Official labeling states that routine monitoring of kidney function is advised for this population.

Q: Can Endari affect liver function?

A: The labeling notes caution for use in patients with pre-existing hepatic (liver) impairment, where routine monitoring is advised. This is related to how the drug is metabolized in the body.

Q: Does Endari affect fertility?

A: The official prescribing information states that there are no adequate and well-controlled human studies on Endari and fertility. Data are insufficient to make conclusions about any potential effects.

Q: Is Endari addictive?

A: The official labeling includes a section on Drug Abuse and Dependence which states that L-glutamine is a naturally occurring amino acid. No abuse or dependence has been reported.

Q: Does Endari help with pain episodes?

A: The medicine is indicated to reduce the acute complications associated with sickle cell disease. Clinical studies examined outcomes related to the frequency of painful episodes, which are known as vaso-occlusive crises (VOCs).

Q: Can Endari be taken with Tylenol or Advil?

A: Official labeling states that no formal studies evaluating Endari’s interactions with other medicinal products, including non-prescription drugs like Tylenol or Advil, have been conducted. This statement reflects the lack of formal studies evaluating interactions with other products.

Q: Are there any known interactions with birth control pills?

A: Regulatory documents state that no formal studies evaluating Endari’s interactions with other medicinal products, including medications like birth control pills, have been conducted. The regulatory profile is defined by this absence of specific interaction data.

Q: Does Endari interact with common cold medicines?

A: The official labeling states that no formal studies evaluating Endari's interactions with other medicinal products, including non-prescription drugs like cold medicines, have been conducted.

Q: Does Endari interact with vitamins or other supplements?

A: The official labeling states that no formal studies evaluating the interaction of Endari with other medicinal products or supplements, including vitamins, have been conducted. This is based on the data available from the regulatory review.

Q: What kind of research supports the use of Endari?

A: The evidence supporting the medicine is based on a randomized, double-blind, placebo-controlled trial. This primary study examined the medicine’s effect on acute complications of sickle cell disease over a 48-week observation period.

Q: Does Endari need to be refrigerated?

A: Unopened packets of Endari should be stored at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F). The product should also be kept away from direct sunlight.

The official regulatory labeling specifies strict conditions for storing and disposing of Endari (L-Glutamine oral powder) to maintain its quality.

Official Storage and Handling

Item	Requirement
Storage Temperature	Store at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F).
Protection	Keep unopened packets away from direct sunlight.
Post-Mixing Stability	The mixed powder must be ingested immediately and cannot be stored for future use; any unused mixed portion must be discarded.
Child Safety	Keep Endari and all drugs out of the reach of children.

Disposal Requirements

Official disposal guidelines instruct users to throw away unused or expired drugs. The medication should not be flushed down a toilet or poured down a drain unless explicitly directed to do so. Consult a pharmacist for information on local medication take-back programs or safe household disposal methods.